By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

MSD invests USD 220 million in Krems

logo MSD © MSD

MSD intends to invest about USD 220 million over the next four to five years in the expansion of the existing Baxter facility, and will create approx. 400 new jobs.

The new production plant will primarily manufacture vaccines. “On the basis of this acquisition, we are positioning ourselves for strong, long-term growth”, states Joseph Morrissey, Vice President of MSD Animal Health. After completing adaptations to the site, the company plans to commence vaccine production in two years. MSD already operates a manufacturing facility in Vienna for veterinary pharmaceuticals via its subsidiary Intervet. It mainly produces hormones, tick protection and control products, cardiovascular medicines and antibiotics. The animal medicines are exported for the most part, especially to the USA. Merck’s animal health division is represented in 50 countries, and its products are available in 150 markets worldwide.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • AAIC - AI in AgriTech

    25.01.2022 - 26.01.2022, virtual

  • ROBOTICS Slovenia 2022

    15.02.2022 - 17.02.2022, Ljubljana, Slovenia

Austria Map

Find the perfect location for your company

Reliability and expertise in the country and in the company are the convincing factors in selecting a business location. We can be justifiably proud but can still become even more attractive. This is something Austria should increasingly work on in the future!

Pfizer

Logo
More testimonials

news from the business location Austria

The path taken by immune cells

In order to combat infections and heal injuries as well as to fight against tumours, immune cells need to enter tissue.

IPCEI on Microelectronics – NXP Contributes Security Technology

Important Projects of Common European Interest (IPCEI) are large-scale innovation programmes in which several EU member states participate. They are designed to sustainably strengthen European value chains in critical technology sectors. Microelectronics comprises one such key technology. Within the context of the IPCEI on Microelectronics, NXP Gratkorn is focusing on the issue of “security,” thus contributing to Europe’s digital sovereignty and the resilience of its critical infrastructures.

More news All blog posts